• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AiCure tests artificial intelligence in opioid trial

AiCure tests artificial intelligence in opioid trial

November 24, 2014
CenterWatch Staff

AiCure, a New York-based artificial intelligence company providing advanced facial recognition and motion-sensing technology to monitor medication ingestion, has announced the start of a major clinical trial to monitor and intervene with patients receiving medication as maintenance therapy for opioid addiction.

Fatal overdoses from prescription opiates have quadrupled in the last 15 years. Opioids now cause more deaths per year than heroin, cocaine and benzodiazepines combined. Overall, the economic cost of opioid abuse is estimated to exceed $55 billion annually. Although adherence to therapy is associated with improved recovery, patients not taking their medication, taking it incorrectly or giving it or selling it to others—which happens frequently—impedes patients and health systems from fully benefiting from treatment.

AiCure has developed a novel platform that can work on any smartphone. Unlike FaceTime or Skype, where there is someone at the other end, in this case artificial intelligence automatically detects in real time whether the person is taking his or her medication as prescribed. Patients who take incorrect doses or do not use the software are automatically flagged for immediate follow-up.

The National Institute on Drug Abuse (NIDA) has provided $1 million in funding to assess whether patients using the AiCure platform are more adherent and whether adoption of the system can improve treatment duration and reduce the risk of relapse. The large trial is being carried out with the Cincinnati Addiction Research Center (CinARC) at the University of Cincinnati. A total of 130 participants will be enrolled over the course of 12 months.

Preliminary results of the trial are expected by August 2015.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing